The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Advanced Paraneoplastic Pemphigus

Severe autoimmune mucocutaneous blistering disease associated with neoplasms (especially Castleman disease, NHL, CLL, thymoma), with high mortality from bronchiolitis obliterans and underlying tumor.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Advanced Paraneoplastic Pemphigus?

PNP was first described by Anhalt 1990. Clinical hallmark is severe, painful, persistent oral mucositis (palate, tongue, lips, oropharynx) often the presenting feature, accompanied by polymorphous skin lesions: bullae, erosions, lichenoid papules, target lesions, and pemphigus-like blisters on trunk and extremities. Conjunctival, esophageal, genital, and respiratory mucosa involvement causes systemic complications.

Pathogenesis: tumor produces antibodies (or alters T-cell tolerance) targeting plakin family proteins of desmosomes and hemidesmosomes; envoplakin and periplakin are most specific. Bronchiolitis obliterans develops in 30-50%, often after initial response, due to autoimmune airway destruction with progressive obstructive lung disease.

Diagnostic criteria (Camisa & Helm modification): mucocutaneous involvement, characteristic histology (suprabasal acantholysis, lichenoid interface change, individual keratinocyte necrosis), direct immunofluorescence (intercellular IgG and complement, plus basement membrane deposition), serum autoantibodies (indirect IF on rat bladder, immunoblot/immunoprecipitation showing plakin pattern), and underlying neoplasm.

Symptoms

Severe, painful, refractory oral mucositis (most prominent feature)
Polymorphous skin lesions: blisters, erosions, target lesions, lichenoid papules
Conjunctival involvement (pseudomembranes, scarring)
Esophageal mucositis (odynophagia, weight loss)
Genital mucosal lesions
Progressive dyspnea (bronchiolitis obliterans development)
Systemic symptoms of underlying malignancy (fever, weight loss, lymphadenopathy)
Failure of conventional pemphigus treatment

Risk Factors

Underlying lymphoproliferative neoplasm (NHL, CLL most common in adults; Castleman disease in young patients)
Thymoma, Waldenström macroglobulinemia
Solid tumors (rare): sarcoma, carcinoma
Adult age (mean 50-65, but pediatric Castleman-associated cases)
No clear genetic predisposition (HLA studies inconclusive)
No infectious or environmental triggers identified

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe persistent oral mucositis unresponsive to standard treatment
  • Polymorphous skin blistering with mucosal involvement
  • New respiratory symptoms (suspect bronchiolitis obliterans)
  • Known lymphoproliferative disease with new mucocutaneous symptoms
  • Dermatology, oncology, and pulmonology multidisciplinary urgent referral

Treatment Methods

01
Diagnostic confirmation: skin/mucosa biopsy (histology + DIF), serum autoantibodies (indirect IF on rat bladder, ELISA for envoplakin/periplakin), imaging (CT chest/abdomen/pelvis) for tumor identification, lymph node biopsy if lymphadenopathy
02
Tumor-directed therapy: complete surgical excision of Castleman disease (curative in localized form); chemotherapy/immunotherapy for NHL, CLL (R-CHOP, BR, ibrutinib); thymectomy for thymoma; rituximab for B-cell tumors and PNP simultaneously
03
Immunosuppression for PNP: high-dose systemic corticosteroids (prednisolone 1-2 mg/kg/day) — initial control but limited efficacy; rituximab (anti-CD20) — first-line for both tumor and PNP autoantibody depletion, often dramatic; IVIG (intravenous immunoglobulin) 2 g/kg over 5 days monthly
04
Adjunctive immunosuppressants: cyclosporine, mycophenolate mofetil, cyclophosphamide, azathioprine; alemtuzumab (anti-CD52) for refractory cases; daclizumab
05
Plasmapheresis or immunoadsorption: rapid autoantibody removal; bridge to other therapies
06
Mucocutaneous care: gentle wound care, topical analgesics (lidocaine, magic mouthwash), nutritional support (often requires NG/PEG feeding due to oral pain), prevention of secondary infection
07
Bronchiolitis obliterans: high-dose corticosteroids, macrolide (azithromycin) anti-inflammatory effect, montelukast, lung transplantation in selected cases (poor outcomes); CT chest at baseline, every 3-6 months
08
Supportive care: pain management, infection prophylaxis (PCP, fungal, viral), nutrition, ophthalmology (conjunctival scarring), gastroenterology (esophageal involvement)
09
Prognosis: mortality 75-90% in classic PNP; better outcomes with localized Castleman disease (cure possible with surgery), early rituximab; worse with NHL/CLL and bronchiolitis obliterans development
10
Multidisciplinary management: dermatology (PNP control), oncology (tumor treatment), pulmonology (BO surveillance and management), ophthalmology, ENT, ICU support
11
Patient and family counseling: severity, prognosis, multimodality treatment burden, palliative care integration when appropriate
12
Emerging therapies: BTK inhibitors for B-cell malignancies and possibly PNP, novel anti-plakin targeted therapies under investigation

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.